Rezolute (RZLT) Cash from Investing Activities (2012 - 2026)
Rezolute (RZLT) reported Cash from Investing Activities of $12.3 million for Q1 2026, down 46.73% on a YoY basis from $23.1 million in Q1 2025, and down 46.17% sequentially from $22.8 million in Q4 2025.
Rezolute (RZLT) Cash from Investing Activities (2012 - 2026) Analysis & Trends
Rezolute (RZLT) has 13 years of Cash from Investing Activities data on file, last reported at $12.3 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 46.73% year-over-year to $12.3 million; the trailing twelve-month figure through Mar 2026 stood at -$33.0 million (down 792.0% YoY), and the FY2025 full-year result was -$14.5 million, down 129.86% from the prior year.
- Cash from Investing Activities declined to $12.3 million in Q1 2026, from $22.8 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $23.1 million in Q1 2025 to a low of -$95.0 million in Q1 2023.
- A 5-year average of -$6.7 million and a median of $2.6 million in 2023 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities jumped 21497.59% in 2023 and tumbled 1996.01% in 2024, its largest moves.
- Tracing RZLT's Cash from Investing Activities over 5 years: stood at -$83000.0 in 2022, then jumped by 21497.59% to $17.8 million in 2023, then slumped by 35.42% to $11.5 million in 2024, then soared by 98.92% to $22.8 million in 2025, then slumped by 46.17% to $12.3 million in 2026.
- Business Quant data shows RZLT's Cash from Investing Activities at $12.3 million in Q1 2026, $22.8 million in Q4 2025, and -$68.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Rezolute | 517.94 Mn | 517.94 Mn | - | 12.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.28 Mn |
| Mar 31, 2026 | 12.28 Mn |
| Dec 31, 2025 | 22.81 Mn |
| Dec 31, 2025 | 22.81 Mn |
| Sep 30, 2025 | -68.49 Mn |
| Sep 30, 2025 | -68.49 Mn |
| Jun 30, 2025 | 346,000.00 |
| Jun 30, 2025 | 346,000.00 |
| Mar 31, 2025 | 23.05 Mn |
| Mar 31, 2025 | 23.05 Mn |
| Dec 31, 2024 | 11.47 Mn |
| Dec 31, 2024 | 11.47 Mn |
| Sep 30, 2024 | -49.41 Mn |
| Sep 30, 2024 | -49.41 Mn |
| Jun 30, 2024 | 19.66 Mn |
| Jun 30, 2024 | 19.66 Mn |
| Mar 31, 2024 | 8.67 Mn |
| Mar 31, 2024 | 8.67 Mn |
| Dec 31, 2023 | 17.76 Mn |
| Dec 31, 2023 | 17.76 Mn |